Aridis Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 6.82 million compared to USD 7.77 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 0.44 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0498 USD | -18.36% | -36.80% | -28.96% |
06-24 | Aridis Pharmaceuticals, Inc. Provides Corporate Update on Recent Developments | CI |
06-24 | Aridis Pharmaceuticals, Inc. announced that it expects to receive $0.299 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-28.96% | 2.66M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- ARDS Stock
- News Aridis Pharmaceuticals, Inc.
- Aridis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023